Successful lead optimization employs integrated drug metabolism and pharmacokinetic (DMPK) strategies to drive drug discovery projects and identify preclinical proof-of-concept compounds and candidate molecules with excellent developability profiles.
Compounds which demonstrate good functional activity are evaluated in in vitro and in vivo DMPK studies to derive in vitro/in vivo correlations, understand liabilities, and inform the design and interpretation of preclinical PK/PD studies to demonstrate target engagement.
In this webinar, we present data and strategies used in the early prediction of human therapeutic dose in drug discovery and share how the information helps de-risk candidate selection. You will leave with an understanding of how early human dose prediction will impact your drug discovery project.
Mike Briggs, PhD
ADME Science Director
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.